VALERIO TX overview

Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO) (the ‘ Company’ ) announces that it has terminated the liquidity agreement entered into on 29 October 2018 with KEPLER CHEUVREUX (the ‘ Agreement’ ). The termination was effective on 19 February 2025. The termination of the Agreement was decided as part of the savings made by the Company given its cash position. The Company does not intend to enter into another liquidity contract at this stage. It should be noted...

Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO) today announced a strategic decision to discontinue all clinical trials and associated activities, including the ongoing VIO-01 trial. This shift was decided by the board of directors in the context of the financing challenges of the Company. The Company’s cash position should enable it to finance its refocused business other the next three months. In the meantime, in addition to the reduction of its expenses, it is...

Regulatory News: At its meeting of November 13, 2024, the Board of Directors of Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO ), (“ Valerio Therapeutics ” or the “ Company ”) decided to appoint Mr Julien Miara as CEO and Chairman of the Board of Valerio Therapeutics, succeeding Ms Shefali Argawal, effective immediately. Future evolutions related to the Company’s governance will be announced at a later date. View source version on businesswire.com:...

Regulatory News: Under the liquidity contract entered into between VALERIO THERAPEUTICS (Paris:ALVIO) and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30, 2023: - 287,160 shares - € 156,554.06 - Number of executions on buy side on semester: 509 - Number of executions on sell side on semester: 492 - Traded volume on buy side on semester: 634,648 shares for € 258,705.74 - Traded volume on sell side on semester: 923,185 shares for € 402,719.91 As a...

Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX), (“ Onxeo ” or “the Company ”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, announced that the Annual General Meeting held today at 2pm CEST was able to validly deliberate with a quorum of 44.12% , with 30 shareholders representing 49,072,091 voting rights. The Annual General Meeting followed the voting recommendations...

Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today announced the availability of preparatory documents for its Combined General Meeting to be held on Tuesday, June 6, 2023 at 2:00 pm at the Renaissance Paris Nobel Tour Eiffel Hotel, 55 avenue Raymond Poincaré, 75116 Paris. The notice of meeting, including the agenda and the...

Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX), hereafter “ Onxeo ” or the “ Company ”, a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today announced the publication of the Company’s 2022 annual financial report. The 2022 annual financial report is available to the public on the Company’s website . About Onxeo Onxeo (Euronext Growth Paris: ALONX) is a...